|
Objective: A retrospective analysis method to compare the efficacy and adverse effects of the treatment of multiple myeloma, T-VAD program with VAD. Methods: The clinical data diagnosed MM patients treated from June 2005 to December 2010, Quanzhou First Hospital, according to the the domestic diagnostic criteria, a total of 46 cases of T-VAD program and VAD regimen cases. Evaluation of T-VAD program group and VAD program group efficacy by detection of serum immunoglobulin, hemoglobin, bone marrow plasma cells, albumin, globulin, creatinine, blood urea nitrogen were. Measurement data with the t test, count data with χ2 test, survival analysis using the Kaplan-Meier method and Log rank test was used for statistical analysis of the results. P lt; 0.05 to be statistically significant. Results: 1. Efficient T-VAD program group of 21 patients, the efficiency of 80.95% total partial remission in 11 cases (52.38%), progress in six cases (28.57%), 4 cases (19.05%); VAD group of 25 cases, efficiency 52%, partial response were obtained in 8 cases (32%), advances in 5 cases (20%), 12 cases (48%); statistical analysis of P = 0.04 (P lt; 0.05), T-VAD The efficacy of the program group was significantly higher than with VAD group. 2. OUTCOME MEASURES after chemotherapy, blood immunoglobulin, hemoglobin, bone marrow plasma cell count, albumin, globulin observed indicators, T-VAD program group and with VAD group were significantly different (P lt; 0.05); creatinine, blood urea nitrogen T-VAD program group and the VAD program group and other indicators, no statistically significant difference (P gt; 0.05); bone marrow plasma cells decreased more than 80%, or reduced to less than 5% T-VAD program group 16 cases (76.19%) the VAD regimen group, 10 patients (40%), and the two groups, P = 0.014 (P lt; 0.05); increased hemoglobin ≥ 20 g / L for T-VAD program group for more than one month in 14 cases (66.67%), the VAD regimen group 8 cases (32%), two groups P = 0.019 (P lt; 0.05). Calcium (gt; 2.982) to restore normal T-VAD program group, 13 cases (61.90%), 6 cases of VAD regimen group (24%), two groups, P = 0.009 (P lt; 0.05). Urine protein was negative, T-VAD program group (28.57%), VAD group and 4 patients (16%) between the two groups, P = 0.303 (P gt; 0.05). Follow-up T-VAD program group with VAD group median overall survival was 29.9 months, 20.2 months, after statistical comparison, P = 0.045 (P lt; 0.05), the difference was statistically significant . T-VAD regimen group with VAD group median progression-free survival were 29.6 months, 18.6 months, by statistical comparison, P = 0.040 (P lt; 0.05), the difference between the two groups was statistically significant. T-VAD regimen group somnolence adverse reactions incidence of 7 cases (33.33%), the VAD regimen group 2 patients (8%), the two groups have a significant difference (P = 0.031); T-VAD regimen group dry mouth incidence of 8 cases (38.1%), the VAD regimen group 2 patients (8%), and the two groups there is a significant difference (P = 0.014); T-VAD regimen group constipation was 9 cases (42.86%), the VAD program group, 3 patients (12%), the two groups have a significant difference (P = 0.018); Other adverse reactions reduce the rate in the white blood cells, platelets lower rate, the rate of infection, bleeding rate, gastrointestinal symptoms incidence of liver function The rate of occurrence of the damage, renal damage incidence, the incidence of numbness, leg edema incidence, T-VAD program group with VAD group had no significant difference (P gt; 0.05). Conclusion: 1.T-VAD program to treat patients with MM were significantly better than with VAD, MM patients as first-line chemotherapy. . Survival analysis and comparison of T-VAD regimen group total free survival and progression-free survival than those with VAD significantly longer. 3. T-VAD regimen group compared with VAD group of adverse reactions in the two groups of leukopenia, thrombocytopenia, infection, bleeding, gastrointestinal symptoms, liver dysfunction, renal dysfunction, numbness, leg edema occurred rates were similar, but slightly more pronounced T-VAD program group drowsiness, constipation, dry mouth, and other adverse reactions.
|